GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Equity-to-Asset

DexCom (DexCom) Equity-to-Asset

: 0.33 (As of Dec. 2023)
View and export this data going back to 2005. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. DexCom's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $2,069 Mil. DexCom's Total Assets for the quarter that ended in Dec. 2023 was $6,265 Mil. Therefore, DexCom's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.33.

The historical rank and industry rank for DexCom's Equity-to-Asset or its related term are showing as below:

DXCM' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33   Med: 0.42   Max: 0.76
Current: 0.33

During the past 13 years, the highest Equity to Asset Ratio of DexCom was 0.76. The lowest was 0.33. And the median was 0.42.

DXCM's Equity-to-Asset is ranked worse than
82.89% of 871 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs DXCM: 0.33

DexCom Equity-to-Asset Historical Data

The historical data trend for DexCom's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.43 0.41 0.40 0.33

DexCom Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.41 0.31 0.34 0.33

Competitive Comparison

For the Medical Devices subindustry, DexCom's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom Equity-to-Asset Distribution

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where DexCom's Equity-to-Asset falls into.



DexCom Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

DexCom's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2068.6/6264.5
=0.33

DexCom's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2068.6/6264.5
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DexCom  (NAS:DXCM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


DexCom Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of DexCom's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


DexCom (DexCom) Business Description

Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Executives
Sadie Stern officer: Chief Human Resources Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman director
Kevin R Sayer director
Jereme M Sylvain officer: SVP, Finance & CAO 6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach officer: SVP, Research & Development 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos director 754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown officer: EVP, Chief Legal Officer 6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli officer: Vice President Legal Affairs 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan officer: EVP Chief Technology Officer C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan officer: EVP Operations 1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller director TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan officer: * 6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj officer: SVP Information Technology 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn officer: EVP, Global Revenue 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121

DexCom (DexCom) Headlines